Research Studies

labs4Studies for Patients with Asthma or COPD

The University of Chicago physicians are currently involved in a number of clinical studies to evaluate new medications and methods to treat diseases.

     1. Protocol #15543B- Pulmonary Research Registry (PRR)

The objective of this registry is to provide researchers and patients the benefits of a coordinated process by which researchers can screen and identify patients who are interested in participating in clinical research.  If you are interested in being listed on this registry, please contact the Asthma and COPD Center at (773) 702-1015.

     2. Protocol #09421B- Chicago Asthma Bio-repository for integrated Research (CABFIR)

The purpose of our new research study is to collect cell samples from your lungs and your blood to find out how lung and blood cells differ between people with and without asthma. Our goal in this large study is to advance biomedical research which we hope may lead to better treatments for asthma.

Inclusion criteria:

  • Must be between 18 and 65 years old
  • Healthy men and women
  • Must have a diagnosis of asthma

Patients will receive up to $550 for participation in this study.

For more information about our research studies, please contact the Asthma and COPD Center directly at (773) 702-1015


     3. Protocol #10-126-B Asthma Patient Registry (APR)

The goal of this registry is to collect information about people with asthma to help us understand the illness and improve care of people with asthma.  The American Lung Association Asthma Clinical Research Centers (ALA-ACRC) is a network of 18 clinical centers (including the University of Chicago) in the United States. The clinics work together and perform studies about asthma.  This patient registry will include people with asthma from all ALA-ACRC clinics.  We will use the registry to describe the type of people treated at the ALA-ACRC clinics and to identify people who may be eligible to participate in future studies.

For more information about this study, please contact Ginny Zagaja at (773) 702-4012.


     4.Protocol # CPR-03434 A Clinical Trial to Evaluate a Non-surgical Treatment Approach in Patients with Emphysema (EMPROVE)

A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the IBV¬ģ Valve System for the Single-Lobe Treatment of Severe Emphysema.

Inclusion Criteria:

  • 40 years of age or older
  • Must meet the criteria of ATS/ERS guidelines for management of stable COPD
  • Must be able to demonstrate physical ability by performing a 6-minute walk
  • Has abstained from cigarette smoking for 4 months and willing to abstain throughout the study

For more information about this study, please contact Cynthia Warnes at (773) 834-8874.

5. Protocol # IRB14-0445 Steroids in Eosinophil Negative Asthma (SIENA)

The purpose of this study is to find out if people should take an asthma controller medication based on the type of inflammatory cells present in their airway.

Inclusion Criteria:

  • 18 years or older
  • Physician-diagnosed asthma or a history or a history consistent with asthma for at least previous 12 months
  • No use of corticosteroid for at least 6 weeks or inhaled corticosteroid for at least 3 weeks
  • No use of leukotriene modifier for at least 3 weeks

For more information about this study, please contact the Asthma & COPD Center at (773) 702-1015

Take this survey to see if you qualify for the SIENA Study:


6. Protocol # IRB13-1432 Isocapnic Hyperpnea Bronchial Provocation Test

The purpose of this study is to determine whether the symptoms of exercise induced bronchoconstriction during or after exercise can be correlated with the degree of hyperpnea suppression by directly measuring the strength of hyperpnea suppression in subjects via both isocapnic hyperventilation testing.

Inclusion Criteria:

  • Age 18-65 years old
  • Physician diagnosis of asthma
  • No inhaled or systemic corticosteroids for the last 4 weeks
  • No symptoms of upper or lower respiratory infection for the last 4 weeks

 For more information about this study, please contact Dana Factor at (773 ) 702-3685